During Q1 2026, the Cemex UK Wellbeing Strategy Group is focussing on Men’s Health, with a focus on prostate cancer and bowel cancer. To support this first campaign, we have launched our new PSA Testing initiative across three of our large Cemex sites. We still have places available at our Northfleet site in the South but watch this space for further news about PSA testing.

Why are we focussing on Prostate Cancer?

Prostate cancer is now the most commonly diagnosed cancer in UK men, affecting tens of thousands of families every year. Across the UK, more than 64,000 men are diagnosed annually, and over 12,000 men die from the disease each year, roughly one death every hour in England. Around 1 in 8 men will develop prostate cancer in their lifetime, and an estimated 540,000 men are currently living with or after prostate cancer.

Risk increases with age, particularly over 50. Family history also raises risk, making awareness especially important for men with a father or brother who has had the disease. One of the biggest challenges is that prostate cancer often has no early symptoms. When symptoms do appear, they may include changes in urination, difficulty starting or stopping urine flow, or blood in urine or semen, but many men experience no warning signs at all. This makes early detection more difficult and reinforces the importance of discussing risk and PSA blood testing with a GP, particularly for higher-risk groups.

PSA Testing

 PSA testing plays a vital role in the early detection of prostate cancer. PSA stands for Prostate-Specific Antigen, a protein produced by the prostate gland. A simple blood test measures PSA levels, which can help identify potential prostate problems before symptoms appear. One of the key reasons PSA testing is so important is early diagnosis – prostate cancer detected early is much more treatable and has significantly higher survival rates. In the UK, around 9 in 10 men diagnosed at the earliest stage survive for at least five years, compared with far lower survival when the cancer is found later. Because early prostate cancer can be silent, PSA testing may be the only early warning sign.

Despite the serious impact of prostate cancer, survival rates have improved. In the UK, nearly 79% of men now survive prostate cancer for 10 years or more, thanks to advances in early diagnosis and treatment. However, the disease remains the third leading cause of cancer death in UK men, with approximately 12,200 deaths per year.

Find out more: 

• Macmillan Prostate Cancer Fact Sheet – how prostate cancer is diagnosed and treated. Download HERE
• Prostate Cancer UK – Know Your Prostate Booklet.  Download HERE
• Prostate Cancer UK – Online Helpline and resources
• Prostate Cancer UK– Online Wellbeing hub
• Prostate Cancer UK– Story of being diagnosed
• Cancer Research UK– Living with prostate cancer
• NHS Help and Support – NHS prostate cancer support

By encouraging conversation, awareness, and early risk checks, we can help more men detect prostate cancer sooner and save lives.